BE Jones, M Otaya, D Antoniskis, S Sian, F Wang, A Mercado, PT Davidson and PF Barnes
Department of Medicine, University of Southern California School of Medicine, Los Angeles 90033.

The purpose of this study was to determine the efficacy and toxicity of a standard antituberculosis regimen in patients with human immunodeficiency virus (HIV) infection. We prospectively evaluated 89 patients with tuberculosis and HIV infection at an urban medical center. Eighty-two patients received isoniazid, rifampin, and pyrazinamide, with or without ethambutol, for 2 mo, followed by isoniazid and rifampin for 7 mo. Seven patients received other regimens because of drug resistance or intolerance. Therapy was self- administered in 57 patients and directly observed in 32 cases. All patients showed rapid clinical improvement during the first month of therapy, and sputum cultures reverted to negative after 3 mo in 52 of 54 patients from whom specimens were obtained. Adverse reactions to isoniazid or rifampin prompted alterations in antituberculosis regimens in five patients (6%). Forty patients (45%) died during follow-up, and tuberculosis was a potential contributory cause of death in three cases. Treatment failure occurred in five patients (6%), four of whom were noncompliant with therapy. The fifty patient had an isoniazid- resistant organism. No relapses occurred in 916 patient-months of follow-up posttreatment. We thus conclude that the 9-mo regimen used for treatment of drug-susceptible tuberculosis in HIV-infected patients is effective and well tolerated.

This article has been cited by other articles:

				P. Nahid, L. C. Gonzalez, I. Rudoy, B. C. de Jong, A. Unger, L. M. Kawamura, D. H. Osmond, P. C. Hopewell, and C. L. Daley Treatment Outcomes of Patients with HIV and Tuberculosis Am. J. Respir. Crit. Care Med., June 1, 2007; 175(11): 1199 - 1206. [Abstract] [Full Text] [PDF]

				N. W. Schluger The Pathogenesis of Tuberculosis: The First One Hundred (and Twenty-Three) Years Am. J. Respir. Cell Mol. Biol., April 1, 2005; 32(4): 251 - 256. [Full Text] [PDF]

				American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 603 - 662. [Full Text] [PDF]

				C MAYAUD and J CADRANEL Tuberculosis in AIDS: past or new problems? Thorax, July 1, 1999; 54(7): 567 - 571. [Full Text]

				D. V. Havlir and P. F. Barnes Tuberculosis in Patients with Human Immunodeficiency Virus Infection N. Engl. J. Med., February 4, 1999; 340(5): 367 - 373. [Full Text] [PDF]

				B. Gravatt Current Concepts in the Pharmacologic Treatment and Management of Tuberculosis The Journal of School Nursing, October 1, 1997; 13(4): 28 - 38. [Abstract] [PDF]

				F. Pulido, J.-M. Pena, R. Rubio, S. Moreno, J. Gonzalez, C. Guijarro, J.-R. Costa, and J.-J. Vazquez Relapse of Tuberculosis After Treatment in Human Immunodeficiency Virus--Infected Patients Arch Intern Med, January 27, 1997; 157(2): 227 - 232. [Abstract] [PDF]

				HIV-Associated TB and Response to Treatment AIDS Clinical Care, February 1, 1995; 1995(201): 8 - 8. [Full Text]